Distinguishing Inflammation from Tumor and Peritumoral Edema by Myeloperoxidase Magnetic Resonance Imaging

Kleijn, Anne; Chen, John W.; Buhrman, Jason S.; Wojtkiewicz, Gregory R.; Iwamoto, Yoshiko; Lamfers, Martine L.M.; Stemmer‐Rachamimov, Anat; Rabkin, Samuel D.; Weissleder, Ralph; Martuza, Robert L.; Fulci, Giulia

doi:10.1158/1078-0432.ccr-11-0575

Cited by 34 publications

(32 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…77,78 The most common triggers for activatable NPs are stimuli such as pH, temperature, redox reactions, 79 metabolites, ions, proteases, ultrasound, and light. 80 The tumor microenvironment regulates tumor progression and the spread of cancer in the body.…”

Section: In Vivo Diagnosis (“Smart Imaging”)mentioning

confidence: 99%

Diverse Applications of Nanomedicine

Pelaz¹,

et al. 2017

View full text Add to dashboard Cite

The design and use of materials in the nanoscale size range for addressing medical and health-related issues continues to receive increasing interest. Research in nanomedicine spans a multitude of areas, including drug delivery, vaccine development, antibacterial, diagnosis and imaging tools, wearable devices, implants, high-throughput screening platforms, etc. using biological, nonbiological, biomimetic, or hybrid materials. Many of these developments are starting to be translated into viable clinical products. Here, we provide an overview of recent developments in nanomedicine and highlight the current challenges and upcoming opportunities for the field and translation to the clinic.

show abstract

Section: In Vivo Diagnosis (“Smart Imaging”)mentioning

confidence: 99%

Diverse Applications of Nanomedicine

Pelaz¹,

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Furthermore, the modest response on MRI does not correlate with clinical endpoints 88 . Therefore, radiologic criteria to evaluate brain tumor immunotherapy have to be refined and the use of more advanced techniques to image inflammation and immune response are needed 89 .…”

Section: Endpoints and Outcomesmentioning

confidence: 99%

Immunotherapy for the Treatment of Glioblastoma

Thomas¹,

Ernstoff²,

Fadul³

2012

The Cancer Journal

View full text Add to dashboard Cite

Glioblastoma, the most aggressive primary brain tumor, thrives in a microenvironment of relative immunosuppression within the relatively immune-privileged central nervous system. Despite treatments with surgery, radiation therapy, and chemotherapy, prognosis remains poor. The recent success of immunotherapy in the treatment of other cancers has renewed interest in vaccine therapy for the treatment of gliomas. In this article, we outline various immunotherapeutic strategies, review recent clinical trials data, and discuss the future of vaccine therapy for glioblastoma.

show abstract

“…CT-2A cells were previously utilized to investigate imaging techniques of murine brain tumors following oHSV treatment, yet no in vitro analyses of oHSV effects on CT-2A cells were reported [65]. CT-2A cells are a murine astrocytoma cell line derived from C57Bl/6 mice.…”

Section: Discussionmentioning

confidence: 99%

Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1

Gaston

Odom

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

Oncolytic type-1 herpes simplex viruses (oHSVs) lacking the γ134.5 neurovirulence gene are being evaluated for treatment of a variety of malignancies. oHSVs replicate within and directly kill permissive cancer cells. To augment their anti-tumor activity, oHSVs have been engineered to express immunostimulatory molecules, including cytokines, to elicit tumor-specific immune responses. Interleukin-15 (IL-15) holds potential as an immunotherapeutic cytokine because it has been demonstrated to promote both natural killer (NK) cell-mediated and CD8+ T cell-mediated cytotoxicity against cancer cells. The purpose of these studies was to engineer an oHSV producing bioactive IL-15. Two oHSVs were constructed encoding murine (m)IL-15 alone (J100) or with the mIL-15 receptor α (mIL-15Rα, J100D) to determine whether co-expression of these proteins is required for production of bioactive mIL-15 from oHSV. The following were demonstrated: i) both oHSVs retain replication competence and cytotoxicity in permissive tumor cell lines. ii) Enhanced production of mIL-15 was detected in cell lysates of neuro-2a cells following J100D infection as compared to J100 infection, suggesting that mIL-15Rα improved mIL-15 production. iii) Soluble mIL-15 in complex with mIL-15Rα was detected in supernates from J100D-infected, but not J100-infected, neuro-2a, GL261, and CT-2A cells. These cell lines vary in permissiveness to oHSV replication and cytotoxicity, demonstrating soluble mIL-15/IL-15Rα complex production from J100D was independent of direct oHSV effects. iv) The soluble mIL-15/IL-15Rα complex produced by J100D was bioactive, stimulating NK cells to proliferate and reduce the viability of syngeneic GL261 and CT-2A cells. v) J100 and J100D were aneurovirulent inasmuch as no neuropathologic effects were documented following direct inoculation into brains of CBA/J mice at up to 1x107 plaque forming units. The production of mIL-15/mIL-15Rα from multiple tumor lines, as well as the lack of neurovirulence, renders J100D suitable for investigating the combined effects of oHSV and mIL-15/IL-15Rα in various cancer models.

show abstract

Distinguishing Inflammation from Tumor and Peritumoral Edema by Myeloperoxidase Magnetic Resonance Imaging

Cited by 34 publications

References 47 publications

Diverse Applications of Nanomedicine

Diverse Applications of Nanomedicine

Immunotherapy for the Treatment of Glioblastoma

Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1

Contact Info

Product

Resources

About